Are elderly women more susceptible to the risk of developing periphe
Research type
Research Study
Full title
Peripheral neuropathy in breast cancer patients who are over 65 years and patients under 65 years undergoing treatment with paclitaxel, a retrospective cohort study.
IRAS ID
222718
Contact name
Tamsin Holt
Contact email
Sponsor organisation
University of Bradford
Duration of Study in the UK
0 years, 8 months, 11 days
Research summary
Paclitaxel-induced peripheral neuropathy (PIPN) is widely acknowledged as a factor limiting the use of paclitaxel. PIPN is estimated to affect between 25 to 75% of patients receiving paclitaxel therapy.
This MSc study will examine the prevalence of peripheral neuropathy among breast cancer women treated with this drug. This will involve the use of medical records for the last three to four years. The study aims to create awareness among clinicians and nursing staff in order for them to make effective decisions and quick intervention in the teaching hospital for service improvement.
The primary question is whether age is a risk factor for developing paclitaxel-induced peripheral neuropathy. A secondary question will be whether elderly women are more prone to experiencing higher grade of paclitaxel induced peripheral neuropathy than younger women.
A retrospective cohort study will be carried out at a single hospital at which the investigator (MSc student) is employed as a chemotherapy nurse. This will involve the investigator examining the medical records of patients from a single hospital who have undergone treatment with paclitaxel. Data collected from these records to address the aims of the study.
REC name
London - Westminster Research Ethics Committee
REC reference
17/LO/0671
Date of REC Opinion
28 Apr 2017
REC opinion
Favourable Opinion